Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma

Abstract Background Based on the results of the PACIFIC trial, maintenance with durvalumab has emerged as the standard treatment following concurrent chemoradiotherapy in patients with unresectable locally advanced non‐small cell lung carcinoma (NSCLC). However, adverse events attributed to durvalum...

Full description

Bibliographic Details
Main Authors: Nobuyuki Hirama, Masaki Yamamoto, Satoshi Nagaoka, Wataru Segawa, Chihiro Sugimoto, Hirokazu Nagayama, Shuntaro Hiro, Yukihito Kajita, Chihiro Maeda, Sousuke Kubo, Kenichi Seki, Yoshinori Nagahara, Shuhei Teranishi, Ken Tashiro, Yu Hara, Nobuaki Kobayashi, Shigenobu Watanabe, Makoto Kudo, Takeshi Kaneko
Format: Article
Language:English
Published: Wiley 2023-09-01
Series:Thoracic Cancer
Subjects:
concurrent chemoradiotherapy
durvalumab maintenance therapy
lung injury predictors
non‐small cell lung carcinoma
Online Access:https://doi.org/10.1111/1759-7714.15042

Internet

https://doi.org/10.1111/1759-7714.15042

Similar Items